Results 121 to 130 of about 2,896 (157)
Some of the next articles are maybe not open access.

Zanubrutinib: First Approval

Drugs, 2020
Zanubrutinib (Brukinsa®), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based
openaire   +2 more sources

Zanubrutinib for the treatment of Waldenström Macroglobulinemia

Expert Review of Hematology, 2020
Introduction: Waldenström Macroglobulinaemia (WM) is a heterogeneous, incurable condition which often relapses after chemoimmunotherapy. Novel therapies such as Bruton tyrosine-kinase (BTK) inhibitors have shown to be efficacious in treating WM but with an established, significant toxicity profile seen in the first-generation inhibitor Ibrutinib ...
Kenneth J. C. Lim, Constantine S. Tam
openaire   +2 more sources

Zanubrutinib (Brukinsa)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Brukinsa (zanubrutinib) should not be reimbursed by public drug plans for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. While evidence from 2 clinical trials showed a response in patients treated with Brukinsa, there is uncertainty in how well patients ...
openaire   +1 more source

Zanubrutinib

Reactions Weekly, 2021
openaire   +2 more sources

Zanubrutinib

Reactions Weekly, 2023
openaire   +2 more sources

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2023
Andrzej Mital, Habte Yimer, Aileen Cohen
exaly  

Clinical Pharmacology and PK/PD Translation of the Second-Generation Bruton’s Tyrosine Kinase Inhibitor, Zanubrutinib

Expert Review of Clinical Pharmacology, 2021
Judith Trotman   +2 more
exaly  

A Phase 1, Open-Label, Fixed-Sequence, Drug–Drug Interaction Study of Zanubrutinib With Rifabutin in Healthy Volunteers

Clinical Pharmacology in Drug Development, 2023
Srikumar Sahasranaman   +2 more
exaly  

Disseminated Fungal Infection in a Patient Receiving Zanubrutinib

Clinical Case Reports (discontinued), 2023
Madalyn Walsh
exaly  

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review

Blood and Lymphatic Cancer: Targets and Therapy, 2023
Ali McBride, Nada Alsuhebany
exaly  

Home - About - Disclaimer - Privacy